{
  "id": "61f5f89b882a024a10000019",
  "type": "yesno",
  "question": "Is Ozanimod effective for Ulcerative Colitis?",
  "ideal_answer": "Yes, Ozanimod is effective for Ulcerative Colitis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33438008",
    "http://www.ncbi.nlm.nih.gov/pubmed/34423657",
    "http://www.ncbi.nlm.nih.gov/pubmed/34587385",
    "http://www.ncbi.nlm.nih.gov/pubmed/27144850",
    "http://www.ncbi.nlm.nih.gov/pubmed/29608575",
    "http://www.ncbi.nlm.nih.gov/pubmed/29766731",
    "http://www.ncbi.nlm.nih.gov/pubmed/27049060"
  ],
  "snippets": [
    {
      "text": "Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34587385",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSIONS: Ozanimod was more effective than placebo as induction and maintenance therapy in patients with moderately to severely active ulcerative colitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34587385",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: There was a high rate of continued study participation and long-term benefit with ozanimod HCl 1 mg daily based on clinical, histological and biomarker measures in patients with moderately to severely active UC in the TOUCHSTONE OLE. [NCT02531126].",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33438008",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ozanimod: A First-in-Class Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34423657",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSION: Ozanimod is another option in the growing arsenal of UC treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34423657",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE: Ozanimod is the first sphingosine 1-phosphate modulator to be approved for UC and is administered orally. Its efficacy profile is comparable with other UC medications.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34423657",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Compared with placebo, ozanimod led to clinical remission in a significantly higher proportion of patients in both the induction and maintenance phase. Additionally, for secondary end points of clinical response, endoscopic improvement, corticosteroid-free remission, and mucosal healing, ozanimod performed significantly better than placebo. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34423657",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ozanimod interferes with migrations of activated T cells to the site of inflammation and is a promising drug for the UC treatment.Key words: Crohns disease - mongersen - monoclonal antibodies - ozanimod - tofacitinib - ulcerative colitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29766731",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SIONS: Ozanimod was more effective than placebo as induction and maintenance therapy in patients with moderately to severely active ulcerative colitis. (Fund",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34587385",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The sphingosine-1-phosphate receptor-1 (S1P1) agonist ozanimod ameliorates ulcerative colitis, yet its mechanism of action is unknown. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27049060",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ozanimod (RPC1063) is a specific and potent small molecule modulator of the sphingosine 1-phosphate receptor 1 (S1PR1) and receptor 5 (S1PR5), which has shown therapeutic benefit in clinical trials of relapsing multiple sclerosis and ulcerative colitis. Ozan",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29608575",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SIONS: Ozanimod was more effective than placebo as induction and maintenance therapy in patients with moderately to severely active ulcerative colitis. (Fun",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34587385",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SIONS: In this preliminary trial, ozanimod at a daily dose of 1 mg resulted in a slightly higher rate of clinical remission of ulcerative colitis than placebo. The ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27144850",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}